Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Sciformix to Reveal Strategic Model for Talent Acquisition at the DIA 50th Annual Meeting

Published: Thursday, May 22, 2014
Last Updated: Thursday, May 22, 2014
Bookmark and Share
New career strategy aims to address talent acquisition and retention requirements for capacity expansion.

Sciformix Corporation will unveil a new strategic model for talent acquisition and retention at the DIA 50th Annual Meeting, San Diego, California, which will take place 15th to 19th June.

The new model will demonstrate the ability to cater for the increasing demand for talent in the CRO industry, enabling capacity expansion without compromising productivity and the quality of deliverables.

The talent pool for the CRO industry is currently at a critical level, with an ever increasing demand for trained candidates, especially in highly skilled roles.

The demand-supply skew has stretched the limit of current hiring practices aimed at external sourcing of experienced talent. The problem is more acute for companies such as Sciformix, that work in areas of high science and high domain where lateral hiring isn’t the solution.

Sciformix has implemented a novel model of systematized training by developing a structured curriculum both for entry level and experienced candidates. By focusing on in-house professional development, the program will provide not only a stream of trained resources, but also make experienced resources productive on complex assignments they don’t have prior experience on.

In a presentation, to take place at DIA 50th Annual Meeting on 19th June, Dr. Samyuktha Ajay, Practice Head for Clinical Research and Post-Approval Support Services at Sciformix, will outline this new strategic initiative and share the experience and benefits of the program.

Dr. Ajay said: “According to various market research reports, the CRO industry is expected to grow to $32.7 billion by next year, to over $65.0 billion by 2021, and has created an increased demand for a rich talent pool of medical, paramedical and science graduates to supply capacity expansion. CROs and their service providers are creating new positions and promoting internal employees which is driving significant movement amongst companies and, thus, creating further resource crunch. Despite candidates being readily available, finding the right match requires the adoption of a multi-dimensional strategy. Through sharing our extensive experience of in-house training at all levels, we aim to project a program which offers a structured career path and excellent retention strategy.”

The DIA 2014 50th annual meeting is the largest multidisciplinary event that brings together the community of life sciences professionals at all levels and across all disciplines involved in the discovery, development and life cycle management of medical products and therapies to patients.

DIA will provide a platform to raise the level of discussion to facilitate innovation that will change the future of health care and it will provide coverage of the full development and life cycle management of process for health care products.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Sciformix Rated Among the ‘Top 20 Most Promising Pharma and Life Sciences Solution Providers’
Sciformix Corporation has been recognized as one of the Top 20 Most Promising “Pharma & Life Sciences Solution Providers - 2016” in a recent feature by Silicon India.
Monday, April 25, 2016
Sciformix Corporation CSO Honoured in PharmaVOICE 100
Dr. Chitra Lele is recognized for pioneering work in service provision across global markets.
Friday, August 01, 2014
Sciformix Awarded Pharmaceutical KPO Entrepreneurial Company of the Year
Company has received this prestigious award from Frost & Sullivan.
Thursday, July 18, 2013
Scientific News
Scientists Find Lethal Vulnerability in Treatment-Resistant Lung Cancer
The study describes how the drug Selinexor killed lung cancer cells and shrank tumors in mice when used against cancers driven by the aggressive and difficult-to-treat KRAS cancer gene.
Drug to Treat Alcohol Use Disorder Shows Promise Among Drinkers With High Stress
The findings suggest that potential future studies with drugs targeting vasopressin blockade should focus on populations of people with AUD who also report high levels of stress.
Advanced Lymphoma in Remission After T-Cell Therapy
63% of trial participants who recieved two-drug combination chemo plus intermediate dose of engineered T cells went into complete remission.
New Treatment for Immune Cancers
Clinical trial shows new drug holds promise for treating advanced mastocytosis.
Sickle Cell Gene Therapy Passes Test
Researchers found a precision-engineered gene therapy virus reduced sickle-induced red-cell damage in mice with sickle cell disease.
Opening Door to Oesophageal Cancer Targeted Treatments
Scientists have discovered that oesophageal cancer can be classified into three different subtypes.
Inovio Launches Zika Vaccine Trial
Inovio launches Zika vaccine trial in midst of Puerto Rico epidemic to explore early signals of vaccine efficacy.
Vitamin C May Boost Leukemia Treatment
Studies show that supplementing an epigenetic cancer drug with vitamin C enhanced the drug's effectiveness.
New Hope for Zika Treatment Found in Large-Scale Screen of Existing Drugs
Johns Hopkins researchers join collaborative group to screen 6,000 existing drugs in hopes of finding treatments for Zika Virus infection
FINCH Filgotinib Phase 3 Program Initiated
Galapagos NV reports the initiation of the FINCH global Phase 3 program in rheumatoid arthritis patient populations.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!